Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (Nasdaq: CTKB) reported a strong second quarter for 2022, with total revenue reaching $40.2 million, a 32% increase from the previous year.
The gross profit stood at $24.6 million, marking a 24% rise compared to Q2 2021, although the gross profit margin decreased to 61% from 65%.
Despite operating expenses rising 60% to $25.5 million, the company expects full-year revenue to be at the higher end of $160 million to $168 million.
Cytek Biosciences, a leader in cell analysis solutions, will participate in the 42nd Annual Canaccord Genuity Global Growth Conference in Boston on August 11, 2022, at 8:00 AM PT. The event will feature a fireside chat with company management, accessible via a live and archived webcast on their website. Cytek's innovative Full Spectrum Profiling technology enhances cell analysis precision and sensitivity. Its products are primarily for research use and have received regulatory approvals in some regions. More details are available on their investor relations page.
Cytek Biosciences (Nasdaq: CTKB) will report its second quarter 2022 financial results after market close on August 10, 2022. A conference call will follow on the same day at 2:00 p.m. PT to discuss the results and future outlook. Cytek is a leader in cell analysis solutions, known for its Full Spectrum Profiling™ (FSP™) technology, which enhances cell analysis precision and multiplexing capabilities. Its FSP platform includes instruments like Aurora and Northern Lights™ and reagents tailored for research purposes only. For more details, visit their investor relations website.
Cytek Biosciences (Nasdaq: CTKB) will host its inaugural Analyst and Investor Day on June 22, 2022, starting at 9:00 a.m. ET. This event aims to showcase Cytek's proprietary cell analysis technologies and related market opportunities, featuring presentations from industry leaders and Q&A sessions with the leadership team. A live webcast of the event will be available on Cytek’s investor relations website, and a replay will follow. Cytek specializes in Full Spectrum Profiling technology, enhancing cell analysis tools.
Cytek Biosciences has announced the availability of its CE-IVD-certified cFluor reagents for clinical diagnostics across Europe. This certification allows Cytek to expand its market presence and offer total cell analysis solutions in hospitals and laboratories. The reagents are produced under rigorous quality controls and validated for optimal performance with Cytek's advanced cell analysis systems. CEO Dr. Wenbin Jiang emphasized the significance of this milestone, indicating a commitment to enhancing diagnostic capabilities across the region.
Cytek Biosciences reported a strong first quarter for 2022, with total revenue reaching $35.1 million, marking a 44% increase year-over-year. The installed base grew to 1,226 instruments after placing 116 instruments in the quarter. Gross profit also rose to $20.2 million, though the gross profit margin slipped to 58% from 60% in 2021. Operating expenses climbed to $22.5 million, leading to a $2.4 million loss from operations. The company forecasts full-year revenue at the high end of $160 million to $168 million.
Cytek Biosciences (Nasdaq: CTKB) will report its Q1 2022 financial results after market close on May 11, 2022. Following the earnings announcement, management will host a webcast conference call at 2:00 p.m. PT / 5:00 p.m. ET to discuss the results, business developments, and future outlook. Cytek is known for its Full Spectrum Profiling™ technology, providing advanced cell analysis solutions.
Cytek Biosciences announces the appointment of Todd Garland as Chief Commercial Officer, effective immediately. Garland, with extensive experience in the life sciences sector, previously held leadership roles at BD Biosciences, CareFusion, and Cardinal Health. His expertise is expected to enhance Cytek's growth and customer service capabilities centered around their Full Spectrum Profiling™ (FSP™) technology. Dr. Wenbin Jiang, CEO, believes Garland's leadership will be pivotal in executing growth opportunities and fortifying the organization’s market position in cell analysis.
Cytek Biosciences reported a 38% revenue growth for 2021, totaling $128 million. In Q4, revenue reached $38.9 million, a 27% increase from 2020. Although gross profit increased to $79.1 million for the year, operating expenses surged by 84% to $70 million, resulting in a decrease in income from operations. Net income fell to $4.4 million for 2021. The company plans for 2022 revenue between $160 million and $168 million and has expanded its manufacturing capacity significantly.
FREMONT, Calif., Feb. 16, 2022 – Cytek Biosciences (Nasdaq: CTKB) announces its participation in the 42nd Annual Cowen Health Care Conference. Management will engage in a fireside chat on March 9th at 8:10 a.m. PT / 11:10 a.m. ET. Interested participants can access the live and archived webcast via the Investors section of Cytek's website.
Cytek is a leader in cell analysis solutions, utilizing its Full Spectrum Profiling™ technology for high-resolution and high-sensitivity analysis. Its platform includes the Aurora and Northern Lights™ systems, and products are primarily for research use.